Since launching our emerging research program in 2019, ACHA has invested $300,000 to fund 10 investigations at ACHD centers across the country. We are excited to build upon our commitment to unlocking new discoveries for our patient population, and are thrilled to announce today that grant applications for ACHA’s 2022 Research Awards are now available!
As we announced in 2018, research is a part of our strategic plan with this overall goal: Fund research to improve the lives of CHD patients and future generations in partnership with medical professionals. We remain committed to funding adult CHD research and are dedicated to providing research funds in 2022 and beyond so that we can continue to support the critical research for all adult CHD patients and their family members.
The Adult Congenital Heart Association (ACHA) has announced the newest additions to the organization’s Medical Advisory Board (MAB), joining dozens of other medical providers specializing in the field of adult congenital heart disease (ACHD) care. ACHA MAB members play a crucial role in offering expert opinions on research and medical developments in ACHD and the needs of the nearly 2 million adults with CHD in the United States to assure that organizational policies meet the highest standards of scientific need and accuracy.
For the second year in a row, we are proud to announce the ACHA annual award recipients! Nominees in the following four categories were submitted by ACHA staff and board members: Fundraiser of the Year, Rookie of the Year, Influencer of the Year, and Organizational Partner of the Year. Once all nominees were submitted, the ACHA Emeritus Board reviewed the nominations and chose the winner for each category.
As 2021 winds down, we reflect back on the accomplishments of the ACHA ACHD Accreditation Program this year. Despite the pandemic, ACHA has continued to move programs forward in the process through virtual site visits and providing valuable feedback to further enhance patient care. We are thrilled to report there are currently 44 programs caring for more than 77,000 patients in a total of 27 states and counting.
Due to successes in treating congenital heart disease (CHD) in childhood, more children with CHD are surviving to adulthood—resulting in more adults with CHD than children in the United States. The number of adults with CHD continues to grow every year.
From its inception more than 20 years ago, the Adult Congenital Heart Association (ACHA) knew our members struggled to find appropriate cardiology care. In 2001, ACHA first endorsed the creation of specialized adult congenital heart disease (ACHD) training.
We mourn the recent loss of Gary D. Webb, MD, an internationally recognized leader in adult congenital heart disease (ACHD), and avid ACHA supporter and champion for the patient voice. Dr. Webb provided leadership and advice for more than two decades as a valued member of both the ACHA Medical Advisory Board and ACHA Emeritus Medical Advisory Board.
Colleges and universities are getting ready to have students back on campus for Fall 2021. Some are requiring that all students be vaccinated with one of the COVID-19 vaccines—Pfizer-BioNTech, Moderna, or Johnson & Johnson—before returning to campus. To see if your school is on that list, click here.
Others are recommending, but not requiring, that students get fully vaccinated before the fall semester starts. Most campuses will have a mixture of students who are fully vaccinated and those who are not.
ACHA has committed $300,000 to 10 grants in our emerging research program since the program launched just two years ago.
As the only national patient advocacy organization specifically funding adult congenital heart disease (ACHD) research only, ACHA aims to partner with specialized medical professionals to improve patient outcomes for current and future generations of ACHD patients.